We are closing out our position in Ruth’s Hospitality for an annualized return of 60%! Read More
Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.
Analyst Articles
USANA Health Sciences develops and makes science-based nutritional and personal care products. USANA also ranks 33rd among all 6,000+ stocks evaluated by our Rapids Profits Matrix for its... Read More
We are selling our position in Juno Therapeutics (JUNO).Last week Juno, a cancer immunotherapy drug maker, announced that it is placing its Phase 2 clinical trial of JCAR015 on hold as the result of the death of one of its trial subjects, and the likely death of a second… Read More
Of all the companies in the S&P 500 Index, only one of them currently earns a perfect score of ‘10’ from my IDEAL Stock Rating System, and that one is Cardinal Health. A month ago its share price took a 15% hit after the company released quarterly earnings that beat expectations, but... Read More
It should come as no surprise that one of our longest-tenured holdings, Paycom Software (PAYC), has accumulated the biggest gain of our Special Situations portfolio stocks. Since we first recommended it in August of 2014 it has racked up a total return of 166%, or about 15 times greater than… Read More
Donald Trump’s unexpected victory ignited an equally unexpected surge in the stock market. Since the date of the election, the S&P 500 Index rose nearly 2% over the next six trading days. That put it back to where it was in early September when most political pollsters thought Hillary Clinton… Read More
We are closing out our position in Valero Energy since it traded below my stop loss price at the opening this morning. Depending on your entry price, the annualized return on this trade should be in the 100 – 150% range if you bought the stock, and much more than that if you purchased call options. Not bad! Read More
- November 17, 2016
-
Download Issue
We said we would deliver huge gains, and we have. Read More
Sturm, Ruger & Company, Inc. is engaged in the design, manufacture and sale of firearms through independent wholesale distributors to the commercial sporting market. Our Rapids Profits Matrix triggered this buy alert when RGR’s share price plummeted last week after Donald Trump’s surprising victory... Read More
Our primary play in the cancer immunotherapy field, Argos Therapeutics (ARGS), issued its third quarter results this morning that were in line with expectations. Shares of ARGS were down slightly in early trading this morning. The company reported a net loss of $0.32 per share compared a loss of $0.97… Read More